Ribociclib with fulvestrant versus physician's choice treatments in patients who recurred after completion of adjuvant cyclin-dependent kinase 4/6 inhibitors as first-line treatment in HR+, HER2-advanced breast cancer
  • Ahn, H.
  • Shin, J.
  • Kim, J.
  • Ahn, J.
  • Park, Y.
Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0
제목
Ribociclib with fulvestrant versus physician's choice treatments in patients who recurred after completion of adjuvant cyclin-dependent kinase 4/6 inhibitors as first-line treatment in HR+, HER2-advanced breast cancer
저자
Ahn, H.Shin, J.Kim, J.Ahn, J.Park, Y.
발행일
2026-02-17
유형
Meeting Abstract
저널명
Clinical Cancer Research
32